Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Advanced Nasopharyngeal Carcinoma
NCT03097939Phase 2Active, not recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Mar 2017
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Centre Singapore. Started Mar 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03097939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097939.